Alzheimer’s disease
-
PublishedNovember 13, 2021
Commentary: The next hospital crisis is coming. Let’s hope the U.S. is prepared
Response teams that respect and protect patients and care providers are one essential solution for behavioral emergencies among people with dementia.
-
PublishedJuly 29, 2021
Research looks for possible COVID-19 link to later Alzheimer’s
Experts stress far more research is needed – and getting underway – to tell if COVID-19 might raise the risk of Alzheimer's or other brain problems later in life, or if people eventually recover from 'brain fog.'
-
PublishedJuly 13, 2021
Medicare evaluating coverage for $56,000 Alzheimer’s drug
Although pricey drugs are now fairly commonplace, the recent approval of Aduhelm prompted an unusually intense backlash.
-
PublishedJuly 9, 2021
FDA chief calls for investigation into review of controversial new Alzheimer’s drug
It's the latest fallout over last month's approval of Aduhelm, an expensive and unproven therapy that the agency OK'd against the advice of its own outside experts.
-
PublishedJuly 8, 2021
FDA reverses itself under pressure, moves to limit use of new Alzheimer’s drug
The Food and Drug Administration says the change is intended to address confusion among physicians and patients about who should get Aduhelm, which has faced an intense public backlash since its approval last month.
-
PublishedJuly 2, 2021
Commentary: The Alzheimer’s mistake by the FDA is already getting worse
Now drugmaker Eli Lilly is pushing forward with another unproven treatment on the basis of limited evidence.
-
PublishedJuly 2, 2021
Our View: With Silver Alerts increasing in Maine, it’s time for a closer look
Since the program was established in 2011, it has helped dozens of missing older Mainers get home. But we don't know a lot more about its effectiveness.
-
PublishedJune 23, 2021
Commentary: Medicare must study unproven, expensive Alzheimer’s drug
Taxpayers and patients cannot afford to pay a high price for a treatment not known to be effective.
-
PublishedJune 20, 2021
Controversial new Alzheimer’s drug gives patients in Maine hope
The treatment developed by Biogen could slow its progression, but health professionals and researchers are divided on whether the FDA was right to approve it.
-
PublishedJune 12, 2021
Another View: Alzheimer’s drug furor highlights U.S. health system’s failures
Is aducanumab a breakthrough or a boondoggle? U.S. health policy offers reason to worry.